We are live on ! Find out more
HS

HighVista Strategies Portfolio holdings

AUM $439M
1-Year Est. Return 289.78%
This Fund
S&P 500
This Quarter Est. Return
+35.32%
1 Year Est. Return
+289.78%
3 Year Est. Return
+622.25%
5 Year Est. Return
+856.34%
10 Year Est. Return
+2,866.87%
AUM
$439M
AUM Growth
+$76.4M
Cap. Flow
-$4.42M
Cap. Flow %
-1.01%
Top 10 Hldgs %
28.21%
Holding
185
New
29
Increased
50
Reduced
66
Closed
38

Top Buys

Rank Stock Value
1
CCCC icon
C4 Therapeutics
CCCC
+$4.61M
2
ALKS icon
Alkermes
ALKS
+$4.14M
3
TNGX icon
Tango Therapeutics
TNGX
+$3.85M
4
RLMD icon
Relmada Therapeutics
RLMD
+$3.12M
5
ELVN icon
Enliven Therapeutics
ELVN
+$2.75M

Top Sells

Rank Stock Value
1
TERN
Terns Pharmaceuticals
TERN
+$6.03M
2
NUVL
Nuvalent
NUVL
+$5.8M
3
SLNO
Soleno Therapeutics
SLNO
+$5.53M
4
SYRE icon
Spyre Therapeutics
SYRE
+$5M
5
APGE icon
Apogee Therapeutics
APGE
+$3.01M

Sector Composition

Rank Sector Weight
1 Healthcare 70.95%
2 Technology 8.26%
3 Miscellaneous 6.43%
4 Industrials 4.96%
5 Financials 2.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GH icon
51
Guardant Health
GH
$21.6B
$2.31M 0.53%
15,419
-7,938
-34% -$863K
AVTX icon
52
Avalo Therapeutics
AVTX
$1.02B
$2.27M 0.52%
122,610
+63,988
+109% +$1.01M
JHX icon
53
James Hardie Industries
JHX
$17.2B
$2.23M 0.51%
85,198
+19,600
+30% +$431K
EYPT icon
54
EyePoint Inc
EYPT
$394M
$2.23M 0.51%
155,704
-27,333
-15% -$366K
MTZ icon
55
MasTec
MTZ
$18.7B
$2.14M 0.49%
5,137
+1,510
+42% +$577K
XENE icon
56
Xenon Pharmaceuticals
XENE
$5.85B
$2.13M 0.49%
35,318
-13,732
-28% -$762K
RBC icon
57
RBC Bearings
RBC
$15.5B
$2.08M 0.47%
3,223
+560
+21% +$333K
V icon
58
Visa
V
$707B
$2.05M 0.47%
5,961
-1,180
-17% -$379K
ASMB icon
59
Assembly Biosciences
ASMB
$736M
$2.02M 0.46%
73,405
-1,330
-2% -$36.2K
STOK icon
60
Stoke Therapeutics
STOK
$1.94B
$2.01M 0.46%
61,316
-1,301
-2% -$41.8K
OLMA icon
61
Olema Pharmaceuticals
OLMA
$939M
$2M 0.46%
160,167
+42,566
+36% +$570K
RKT icon
62
Rocket Companies
RKT
$40.3B
$1.98M 0.45%
125,530
+33,100
+36% +$477K
XPO icon
63
XPO
XPO
$21.6B
$1.98M 0.45%
9,623
+700
+8% +$148K
WDC icon
64
Western Digital
WDC
$159B
$1.95M 0.44%
3,050
-1,050
-26% -$511K
CORZ icon
65
Core Scientific
CORZ
$5.75B
$1.94M 0.44%
75,712
-27,700
-27% -$652K
TXN icon
66
Texas Instruments
TXN
$232B
$1.94M 0.44%
+6,500
New +$1.8M
KBR icon
67
KBR
KBR
$4.7B
$1.87M 0.43%
54,206
+14,800
+38% +$516K
FLS icon
68
Flowserve
FLS
$9.81B
$1.85M 0.42%
24,958
– –
GOOG icon
69
Alphabet (Google) Class C
GOOG
$4.15T
$1.81M 0.41%
5,127
-350
-6% -$125K
STX icon
70
Seagate
STX
$181B
$1.8M 0.41%
1,870
-1,030
-36% -$786K
MIRM icon
71
Mirum Pharmaceuticals
MIRM
$6.14B
$1.74M 0.4%
14,892
-671
-4% -$67.4K
DNOW icon
72
DNOW Inc
DNOW
$2.86B
$1.72M 0.39%
+132,900
New +$1.73M
ON icon
73
ON Semiconductor
ON
$28.7B
$1.72M 0.39%
18,200
-9,800
-35% -$1M
NUE icon
74
Nucor
NUE
$59.5B
$1.69M 0.39%
+7,600
New +$1.72M
TDAY
75
USA Today Co
TDAY
$950M
$1.61M 0.37%
+188,500
New +$1.42M
1 2
3
4 5

Similar funds

OGM
OnyxPoint Global Management New York $439M AUM 52.19% 1-Year Est. Return
NCM
New Capital Management Houston, Texas $439M AUM 16.55% 1-Year Est. Return
BCC
Bridge City Capital Lake Oswego, Oregon $438M AUM 64.84% 1-Year Est. Return
ASW
Astoria Strategic Wealth Conroe, Texas $438M AUM 16.79% 1-Year Est. Return
CNC
Citizens & Northern Corp Wellsboro, Pennsylvania $438M AUM 26.63% 1-Year Est. Return
TAA
Turiya Advisors Asia Hong Kong $440M AUM 152.81% 1-Year Est. Return
PMA
Prudent Man Advisors Naperville, Illinois $438M AUM 34.49% 1-Year Est. Return
FW
Fairway Wealth Independence, Ohio $437M AUM 19.74% 1-Year Est. Return

HighVista Strategies's Q2 2026 Portfolio in Review

As of Q2 2026, HighVista Strategies held 185 positions worth $439M, up 21% from $362M the previous quarter. Its ten largest holdings account for 28% of the portfolio.

HighVista Strategies's Q2 2026 filing shows 29 new, 50 increased, 66 reduced and 38 closed positions. Its largest new stake was C4 Therapeutics: 1,348,136 shares worth $6.3M. The largest sale was Terns Pharmaceuticals, an estimated $6.03M.

By sector, the portfolio is most concentrated in Healthcare at 71% of assets, up from 67% a quarter earlier, followed by Technology and Miscellaneous.

  • HighVista Strategies's largest Q2 2026 buy was C4 Therapeutics: 1,348,136 shares worth $6.3M.
  • HighVista Strategies added most to Alkermes in Q2 2026, an estimated $4.14M increase.
  • HighVista Strategies's biggest Q2 2026 reduction was Spyre Therapeutics, cutting an estimated $5M.
  • HighVista Strategies fully exited Terns Pharmaceuticals in Q2 2026, selling an estimated $6.03M.
  • HighVista Strategies's ten largest holdings make up 28% of its $439M portfolio in Q2 2026.
  • HighVista Strategies opened 29 new positions and closed 38 in Q2 2026.
  • HighVista Strategies's portfolio value rose 21% quarter-over-quarter to $439M.

Based on HighVista Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.